104508-24-9

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMOMETHYL-2-CYANOPYRIDINE is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique structure allows for the creation of new drug candidates with potential therapeutic applications, leveraging its reactivity in chemical reactions to form a diverse range of medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 6-BROMOMETHYL-2-CYANOPYRIDINE is utilized as a precursor in the synthesis of agrochemicals. Its ability to undergo various chemical reactions makes it instrumental in the production of compounds with pesticidal or herbicidal properties, contributing to the development of effective crop protection agents.
Used in Organic Synthesis:
6-BROMOMETHYL-2-CYANOPYRIDINE is employed as a versatile building block in organic synthesis. Its reactivity and capacity to participate in a wide array of chemical reactions render it invaluable for the synthesis of a broad spectrum of organic compounds, expanding the horizons of chemical research and innovation.

InChI:InChI=1/C7H5BrN2/c8-4-6-2-1-3-7(5-9)10-6/h1-3H,4H2

Upstream product

• 1620-75-3 2-Cyano-6-methylpyridine 

Downstream Products

• 92532-26-8 6-[[3-(1-Hydroxyhexyl)phenoxy]methyl]picolinyl nitrile 
• 50501-38-7 6-(hydroxymethyl)pyridine-2-carbonitrile 
• 85148-95-4 6-cyano-2-pyridinecarboxaldehyde 
• 1202402-79-6 (S)-(6-(((tetrahyd rofuran-3-yl)oxy)methyl)pyridin-2-yl)methanamine 
• 871492-88-5 (R)-(3-{4-[(6-cyano-pyridin-2-ylmethyl)-(4-methoxy-phenyl)-amino]-piperidin-1-yl}-butyl)-carbamic acid tert-butyl ester 
• 92532-25-7 Methyl-6-[[3-(1-hydroxyhexyl)phenoxy]methyl]picolinate 
• 92532-09-7 6-[[3-(1-Hydroxyhexyl)phenoxy]methyl]picolinic acid 

Relevant academic research and scientific papers

A ferrous center as reaction site for hydration of a nitrile group into a carboxamide in mild conditions

Mild conversion of the nitrile substituent into an amide functional group is observed upon coordination of CNTPA [CNTPA = (6-cyano 2-pyridylmethyl)bis(2-pyridylmethyle)amine] to FeCl2 followed by reaction with water. The crystal structure of CNTPAFeCl2 is reported and reveals that the nitrile group does not coordinate but is activated in the vicinity of the ferrous center. Upon treatment with water under anaerobic conditions, CNTPAFeCl2 converts into H2NCOTPAFeCl2, [H2NCOTPA = (6-carboxamido 2-pyridylmethyl)bis(2-pyridylmethyle)amine], the X-ray crystal structure of which is reported. The new ligand H2NCOTPA can easily be obtained upon decomplexation. Copyright

BICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Effect of substituent in pyridine-2-carbaldehydes on their heterocyclization to 1,2,4-triazines and 1,2,4-triazine 4-oxides

A series of substituted pyridine-2-carbaldehydes were brought into heterocyclization with isonitrosoacetophenone hydrazones, followed by aromatization by the action of oxidants or by dehydration in boiling acetic acid. As a result, substituted 3-(pyridin-2-yl)-1,2,4-triazines or 3-(pyridin-2-yl)-1,2,4-triazine 4-oxides were formed. 6-Formylpyridine-2-carbonitrile failed to undergo heterocyclization, 6-methylpyridine-2-carbaldehyde and methyl 6-formylpyridine-3-carboxylate can be converted to both 1,2,4-triazine and 1,2,4-triazine 4-oxide derivative, and only 1,2,4-triazine 4 oxides were obtained from 6-bromopyridine-2-carbaldehyde and 6-formyl-3-phenylpyridine-2-carbonitrile. Convenient procedures were proposed for the synthesis of some initial pyridinecarbaldehydes.

COMPOUNDS USEFUL AS LIGANDS AND PARTICULARLY AS ORGANIC CHROMOPHORES FOR COMPLEXING LANTHANIDES AND APPLICATIONS THEREOF

The invention relates to the use of compounds comprising at least one 2-(1H-tetrazol-5-yl)pyridine unit, of formula (I) below: as ligands for lanthanides and, more especially, as organic chromophores for complexing these elements. It also relates to lanth

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.